Linked Life Data

19822302

Source:http://linkedlifedata.com/resource/pubmed/id/19822302

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2009-10-13
pubmed:abstractText
We sought to reduce the risk of infectious complications and nonrelapse mortality (NRM) associated with the use of antithymocyte globulin (ATG) without compromising control of acute graft-versus-host disease (aGVHD) in patients undergoing reduced-intensity conditioning (RIC) transplantation. As part of an ongoing quality improvement effort, we lowered the dose of rabbit ATG from 7.5 mg/kg of ATG (R-ATG) (n = 39) to 6.0 mg/kg of ATG (r-ATG) (n = 33) in association with fludarabine (Flu) and busulfan (BU) RIC transplantation and then monitored patients for adverse events, relapse, and survival. Of the 72 mostly high risk (82%) patients studied, 89% received unrelated donor allografts, 25% of which were HLA-mismatched. No differences in posttransplantation full donor-cell chimerism rates were observed between the 2 ATG-dose groups (P > .05). When R-ATG versus r-ATG patients were compared, we observed no significant difference in the cumulative incidence of grade II-IV aGVHD (32% versus 27%; P = .73) or grade III-IV aGVHD (23% versus 11%; P = .28). However, the r-ATG group had significantly less cytomegalovirus (CMV) reactivation (64% versus 30%; P = .005) and bacterial infections (56% versus 18%; P = .001), a better 1-year cumulative incidence of NRM (18% versus 3%; P = .03), and a trend for better 1-year overall survival (OS) (64% versus 84%; P = .07) compared to R-ATG patients. A seemingly modest reduction in the dose of rabbit ATG did not compromise control of aGVHD or achievement of donor chimerism, but led to a significant decrease in the risk of serious infections and NRM in high-risk RIC allograft recipients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1523-6536
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1422-30
pubmed:meshHeading
pubmed-meshheading:19822302-Adult, pubmed-meshheading:19822302-Aged, pubmed-meshheading:19822302-Animals, pubmed-meshheading:19822302-Anti-Infective Agents, pubmed-meshheading:19822302-Antilymphocyte Serum, pubmed-meshheading:19822302-Busulfan, pubmed-meshheading:19822302-Disease Susceptibility, pubmed-meshheading:19822302-Female, pubmed-meshheading:19822302-Graft vs Host Disease, pubmed-meshheading:19822302-Hematologic Neoplasms, pubmed-meshheading:19822302-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:19822302-Humans, pubmed-meshheading:19822302-Immunocompromised Host, pubmed-meshheading:19822302-Immunosuppressive Agents, pubmed-meshheading:19822302-Infection, pubmed-meshheading:19822302-Infection Control, pubmed-meshheading:19822302-Male, pubmed-meshheading:19822302-Medical Audit, pubmed-meshheading:19822302-Methotrexate, pubmed-meshheading:19822302-Middle Aged, pubmed-meshheading:19822302-Myeloablative Agonists, pubmed-meshheading:19822302-Patient Isolation, pubmed-meshheading:19822302-Postoperative Complications, pubmed-meshheading:19822302-Rabbits, pubmed-meshheading:19822302-T-Lymphocytes, pubmed-meshheading:19822302-Tacrolimus, pubmed-meshheading:19822302-Transplantation, Homologous, pubmed-meshheading:19822302-Transplantation Conditioning, pubmed-meshheading:19822302-Vidarabine, pubmed-meshheading:19822302-Young Adult
pubmed:year
2009
pubmed:articleTitle
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
pubmed:affiliation
Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA. mehdi.hamadani@gmail.com
pubmed:publicationType
Journal Article, Clinical Trial